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Sumuary Interferon alpha-2a (IFN-a) and fohinc acid (FA) have been shown to modulate the cytotoxic
effects of 5-fluorouracil (5-FU) in the treatment of cancer. A phase II study was initiated to evaluate the effect
of a combination of 5-FU/FA/IFN-a in patients with advanced pancreatic cancer. Sixty previously untreated
patients with advanced adenocarcinoma of the pancreas were treated with 500 mg m- FU via an intravenous
bolus 1 h after the initiation of a 2 h infusion of 500 mg m-2 FA. Before starting the FA infusion, 6 million
units (MU) of IFN-a was administered subcutaneously. The treatment was repeated once a week. Of 57
evaluable patients, eight (14%) had a partial response (PR), eight (14%) a minor response (MR) and 28 (491/.)
no change of disease (NC). Thirteen patients (23%) had progressive disease (PD). The median survival time
was 10 months for all patients, 22 months for patients with partial remission and 5 months for patients with
progressive disease. Many patients with tumour-related pain whose tumours were affected in terms of PR,
MR, NC were free of pain during treatment with this regimen (22/36 patients). The common toxicities
observed were fever (56%), nausea (37%) and diarrhoea (33%). These data suggest that biochemical
modulation of 5-FU with FA and IFN-a has some positive effects in the treatment of pancreatic cancer of
moderate toxicity.
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Pancreatic cancer is often diagnosed when the disease is far
advanced. Only a minority of patients can be cured by
surgery after early diagnosis. Patients with inoperable pan-
creatic cancer have a limited survival rate, averaging only 3-4
months (Warshaw et al., 1992; Brennan et al., 1993). The
results of chemotherapy for pancreatic carcinoma have
generally been disappointing, and only a few agents appear
to have a proven therapeutic effect. 5-Fluorouracil is the
most evaluated and commonly used single agent. Response
rates achieved range from 10 to 20%. Other substances, such
as mitomycin, ifosfamide or epirubicine, do not induce
greater response rates. Furthermore, combination therapies
are not superior to single-agent 5-FU and cause more side-
effects (Cullinan et al., 1990; Kelsen et al., 1991; Wils, 1991;
Warshaw et al., 1992; Brennan et al., 1993). However, 5-FU
alone does not improve survival rates, and to date
chemotherapy must be considered experimental in this
disease. Attempts to improve the therapeutic efficacy of 5-FU
are focused on the principles of 'biomodulation' of the cel-
lular effects of its metabolites. Preclinical studies with
biomodulators such as folinic acid or IFN-a have shown an
augmentation of the 5-FU cytotoxicity against tumour cells
by increasing the 5-FU-induced inhibition of key enzymes of
de novo DNA synthesis. Folinic acid enhances the 5-FU-
induced inhibition of thymidilate synthetase and IFN-a
inhibits thymidine kinase (Ernstoff et al., 1989, Grem et al.,
1992; Van der Wilt et al., 1992). Considering that some
clinical trials on the biomodulation of 5-FU with IFN-a
and/or folinic acid in colorectal carcinoma have been success-
ful, similar therapy regimens seem to be worth testing in
pancreatic cancer (Petrelli et al., 1987, 1989; Wadler et al.,
1989; Bukowski et al., 1991; Piedbois et al., 1992; Sobrero et
al., 1992).
We therefore conducted a pilot study to evaluate the toxi-
city of the combination 5-FU/FA/IFN-a in patients with
pancreatic cancer by adding IFN-a to the schedule of 5-FU
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and FA (Knuth et al., 1992), which had been introduced by
Petrelli et al. in colorectal cancer (Petrelli et al., 1987, 1989).
Because of the promising trends shown there, we initiated
this phase II trial to study the efficacy and the toxicity of the
double modulation of 5-FU through FA and IFN-a in a
larger group of patients.
Patets and methods
Eligibility criteria
All patients had histologically proven, progressive adenocar-
cinoma of the pancreas. Inoperability was defined by com-
puterised tomographic (CT) scan and in some borderline
cases by additional angiography. All patients had bidimen-
sionally measurable tumour parameters. Patients were fol-
lowed for 6 weeks pnror to treatment to document progres-
sive disease before therapy was initiated. The criteria for
tumour progression prior to therapy were not strictly accord-
ing to the WHO classification which was used for the re-
sponse criteria because advanced pancreatic carcinoma causes
death in a very short period of time, even if the tumour does
not grow >25% in cross-sectional area. Patients suffering
from tumour-related symptoms (e.g. pain) were classified as
having a progressive disease and treatment was started at
once. Eligibility requirements included adequate bone mar-
row (WBC > 3.5 x 10 1', platelet count ) 100 x I0 1'),
liver (serum bilirubin , 85pmol 1') and kidney function
(serum creatinine . 150 ytmol 1'). Furthermore, Karnofsky
performance status had to be 60% or greater and estimated
life expectancy more than 8 weeks. Patients with CNS metas-
tases, prior external beam radiation therapy of tumour
manifestations or concomitant malignancies were ineligible.
A formal consent to participate in this protocol was required
from all patients.
Stud) design
The study regimen was designed as follows: 500 mg m-2
5-FU as i.v. bolus 1 h after initiation of a 2 h infusion of
500 mg m-2 folinic acid and 6 MU of IFN-a (Roferon,5.F hue acid md Ilk iv -ooo -w
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Hoffman-LaRoche, Germany) subcutaneously once a week
(Figure 1). Patients were questioned about side-effects by the
responsible physician before each weekly dose. Treatment-
related toxicities were docmented using the grading of the
'World Health Organization' (WHO) (Miller et al., 1981).
Patients with stomatitis, diarrhoea or myelosuppression
WHO grade 2 during therapy received a 20% reduced dose
of 5-FU (400mg m2). Treatment was postponed when side
effects of WHO grade s2 occurred. After recovery, the
therapy was continued with a reduced 5-FU dosage
(400 mg m-). The dose of IFN- was modified if there were
neurological symptoms or worsening of performance status
attributed to treatment (3 MU). End points of therapy
included complete response to therapy, partial response,
minor response and disease stabilisation for more than 2
months, progressive disease or unacceptable toxicity not re-
sponding to dose modification. When PR, MR or NC was
demonstrated, treatment was continued for additional 8 weeks
in order to confirm the maximal inducible resonse. After the
greatest possible response had been achieved, treatment was
not maintain. However, when tumour progression reoccur-
red during treatment pause, therapy was restarted.
Response criteria
Patients were evaluated using weekly histories including
physical examination and blood counts. Utilisation and
dosage of narcotic medications were documented once a
week. All patients suffenng from tumour-related pain
received morphine-based analgesics at the beginning. Pain
reliefwas called 'disappearance ofpain' in those patients who
did no longer need any kind of analgescs. Radiological
examinations and sonographic or CT scans of measurable
tumour parameters were performed every 4 weeks. 'Complete
response' (CR) was defind as total disappearance of all
tumour manifestations initially observed with no evidence of
new areas of malignant disease. 'Partial response' (PR)
required a greater than 50% reduction in the sum of the
products of the longest perpendicular diameters of all
measurable indicator lesions. Tumour reduction smaller than
50% for more than 2 months was designated 'minor res-
ponse' (MR) and tumour stabisation longer than 2 months
as 'no change' (NC). 'Progressive disease' (PD) was defined
as a greater than 25% increase in known malignant disease.
Development of ascites was also valued as disease progres-
sion. Tumour markers CEA and CA19-9 were measured
before and routinely every 4 weeks dunng therapy. Tumour
marker regression ofmore than 20% was defined as 'decrease
in tumour markers'. When both tumour markers were
elevated, only the parallel reduction in CEA plus CAl9-9
was measured as a 'decrease'.
Statistical analysis
Survival curves were estimated by lifetable analysis using the
Kaplan-Meier method (Kaplan et al., 1958). To compare
survival rates, we calulated the median survival time and
progression-free survival time. The number of events was
described by proportions in per cent and the exact confidence
interval of proportions.
5-Fluorouracil, 500 mg m-2 i.v., once a week
Folinic acid, 500 mg m-2 i.v., once a week
Interferon alpha-2a, 6 mu sc., once a week
IFN-a-2a
0
5-FU
1 2h
Figwe 1 Therapy schedule.
ResdJs
Patients
A total of 60 consecutive patients were entered into this trial.
Fifty-seven patients were evaluable for response; three
patients were not evaluable because of 'loss to follow-up'.
Nearly all patients (56/57) had a primary tumour or a local
relapse, 25/57 patients had additional metastases and 1/57
patients had only metastases without evidence of a local
tumour recurre. Further details of the patient characteris-
tics are described in Table I.
Reponse
Partial responses were observed in 8 of 57 (14%) patients
(exact 95% confidence interval, 7-26%; Table II). The re-
sponse durations in these eight patients were 2-10months.
There were no complete responses to therapy. Eight patients
(14%) had a minor response, i.e. a tumour reduction smalkr
than 50%, and 28 patients (49%) had stable disease. Thirteen
patients (23%) experinced a disease progresion. In rneraL
metastases of the lung were more sensitive to therapy than
liver metastases or primary tumours. In the five patients with
primary tumours and additional lung metastases, regression
ofthe lung nodules was observed after 4-8 weeks oftjerapy,
even though the primary tumour shrank at a later time point
(one patient), regressed less than the lung nodules (one
patient) or was progressive (three patients). Many patients
with tumour-related pain (22/36) experienced relief in
association with a PR, MR or NC of measurable disease
(Table III). A decrease in elevated tumour markers (CEA,
CAl9-9) was observed in 14/20 patients with pain relief. This
indicates that a minimal tumour reduction, which could not
be detected by CT, might be sufficient for the reported pain
relief. As soon as tumour-related pain disappeared, treatment
with morphine-based analgesics was ended. If tumours pro-
gresed while treatment was suspended, therapy was re-
staed. Interestingly, 3/9 patients responded again during the
second course of therapy (1/9 PR; 1/9 MR; 1/9 NC).
Table I On study patients characteristics (n = 57)
Sex (F/W 15/42
Age (median, range) 60 (32-79)
KPS (median, range) 80 (60-100)
Site of disea
Pancreas only 31
Pancreas plus metastases 25
Metastases only I
Table n Response to therapy (n = 57)
Partial response 8/57
Minor response 8/57
No change 28/57
Progressive disea 13/57
Median pro on-free time (months)
All patients 5
Responding patients (PR) 9
Median survival time (months)
Al patients (range) 10
Responding patients (PR) 22
Patients with local disea 8
Patients with additional mestases 10
Table m Tumour-related pain dependent on the treatment scc
(n = 36)
Twnour-related pain
More Sae Diapeared
Partial-sponse (5) 0/5 0/5 5/5
Minor response (2) 0/2 0/2 2/2
No change (20) 0/20 5/20 15/20
Progression (9) 6/9 3/9 0/9
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Fgwe 2 Probability of survival after the initiation oftherapy in
57 cdigible patients.
Median progression-free interval from the beginning of
therapy was 5 months for all patients and 9 months for
paients with partial rmission. At the time ofanalysis, 17 of
57 patients (30%) were alive and 40 of 57 patients (70%) had
died. The median duration of survival was 10 months for all
patients, 22 months for patients achieving a partal remission
and 5 months for patients with progressve disea (Table II;
Figure 2). There was no signnt survival difference
between patients with locoregional diseas only (8 months)
and patients with distant metastases (10 months).
Toxicity
Toxicity data are presented in Table IV for al eligible
paients with at least 4 weeks follow-up (n = 57). The most
prominent toxicity associated with 5-FU was nausea (21/57;
37%), which was suppressed in all patients by antemetic
treatment during the following cyces of therapy. Diarrho,
observed in 19/57 patients (33%), was a common gstrointes-
tinal side-effect, which disappeared regularly after dose
reduction of 5-FU. Stomatitis was a rare sde-effect (1/57
patients) and severe myekouppression did not occur. The
most frequently observed side-effects caused by interferon-a
were fever (56%) and fatigue (28%). Fatal treatment-relate
neurological disorders described previously were not
observed (Wadler et al., 1989). However, it cannot be for-
mally ruled out that one observed stroke may have been
induced by IFN-a. In this and two other patients the treat-
ment had to be interrupted because ofintolerable ide-effects:
one patient experienced worsening of her asthma and a
second icreased severity of angina pectoris. No treatment-
related death was encountered.
A focus in the chemotherapy of advaned pancreatic cancer
has been to maxmise the efficacy of 5-FU through bio-
modulation. While biomodulation of 5-FU has mainly been
tested in colorectal cancer, there are only a few cinical
reports of this approach in the therapy of pancreatic cancer.
This clinical trial was initiated to evalhae the effects of the
combination '5-FU/FA/IFN-a' in advanced pancreatic canr.
The preliminary results of this triple combination used as
first-line therapy are encouaging. In spite of the low ovrall
response rate (14%) and the lack of complete Lemissions,
most of the patients ex ienced pallation. No evidence of
tumour progression in the first 2 months was documented in
77% of the patients (PR, MR, NC). In 22 ofthe 36 paients
who suffered from tumour-related pain, pre-existing pain
disappeared during treatment (60%), reardlss ofthe quality
ofresponse (PR, MR or NC). We suggest that the reason for
Taie IV Maximum toxicity (n = 57)
WHO grade
0 1 2 3 4
Anaemia 53 2 1 1
Tlromboyonia 56 1
Leuxocytopenia 54 1 2
Fever 25 8 21 3
Fatigue 41 10 5 1
Nausea 36 12 6 3
Diarrhoea 38 8 5 6
Stomatitis 56 1
Coniuntivits 50 5 2
Skin irritation 53 2 2
treatment-related pain relef-even in patients with stable
diseas-is a reduction of tumour infiltration into the coeliac
plexus, which cannot be detected by CT. Interestingly, in
many patients with pain reduction, a decrease in elevated
tumour markers (CEA and/or CA19-9) was observed (14/20
patets).
Toxicties wer primarily moderate and responded to dose
reduction or specific therapy of the sid-effects. Therefore
treatment could be carred out in an out-patient setting,
which generally is considered an advantage in the palliative
tratment of cacer. Moreover, the treatment was not con-
tinuous. Therapy was suspended when a stable 'resonse' to
therapy - i.e. a partial remission, minor resonse or tumor
stabiisation-was achieved over a period of at least 2
months. If the tumour progsse during a treatment-free
intervaL therapy was restarted. The overall survival period of
10 months for all patiets appears to be superior to reported
survial times of3-6 months with 5-FU monotherapy (Bren-
nan et al., 1989;, Cullinan et al., 1990; Wils, 1991).
Other trials using IFN-a or/and folinic acid in advanced
pancreatic cancer have shown marginal activity with respect
to response rates and survival (Crown et al., 1991; DeCaprio
et al., 1991; Pazdur et al., 1992; Scheithauer et al., 1992;
Weinerman and McCormick, 1992; Rubin et al., 1992).
Scheithauer et al. (1992) recently reported an overall survival
time of 5.5 months for patients treated with '5-FU/FA/IFN-
a' and Weinermann and McCormick (1992) observed an
overall survival time of 20 weeks. Whether these contradic-
tory results are due to patient selection or to different treat-
ment scheduks remains to be seen.
Patients with pancreatic carcinoma frequently present with
a low performance status, signs of malabsoon owing to
panceatic excrory dysfimction, weight oss, abdominal
pain, bowel dysmotility and obstrucive jaundice. Because of
this constellation of symptoms, most patients do not tolerate
sidefects of intensive chemotherapy, but require pallative
therapy. Hence, criteria for successfl therapy must be not
only reponse rate and survival, but also treatment-related
toxicity and quality of life. The data from our study suggest
that combination of 5-FU with FA and IFN-a has moderate
sdeffects and may alleviate or abolsh pre-eisting tumour-
related pain. In this respect study patients experienced a
palliative benefit from this therapy schedule.
The trnds observed,in this phase II trial are promising,
but further clnical trials are necesary to confirm our
prelminary rsults. To date it is still unclear if 5-FU/FA/
IFN-a renders any advantage over 5-FU alone or in com-
bination with FA in the treatment of pancreatic cancer. We
have started a randomised trial in order to compare the
effectiveness of the combination '5-FU/FA/IFN-c' with '5-
FU/FA' alone. This phase III trial will evaluate study
parameters regarng quality oflife besides response rate and
survival.
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